Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Which Are The Toughest Diseases Area To Achieve Clinical Success In?

Executive Summary

In the last decade, on average, only one in 10 Phase I drug development programs conducted in the US have successfully advanced all the way to FDA approval. Meanwhile, despite more than a third of industry's R&D budget being spent on Phase III trials, 42% of programs fail to progress from there, according to a new report from BIO and Informa's Pharma Intelligence.